TEV-53408
DrugSolution for subcutaneous (sc) injection
NCT Number: NCT06807463
The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.
The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.
A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.
The expected trial duration per participant is approximately 86 weeks.
This study is active but is not currently recruiting participants.
Notify Me18 year–64 year
All sexes
Interventional
Phase 2
Teva Investigational Site 78139, Fitzroy, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
NOTE - Additional criteria apply, please contact the investigator for more information.
Exclusion criteria
NOTE- Additional criteria apply, please contact the investigator for more information
Solution for subcutaneous (sc) injection
Solution for subcutaneous (sc) injection
Time frame: Baseline, Week 8
Vh:Cd is used to assess the severity of celiac disease. It is calculated by dividing the villous height by the crypt depth. A lower ratio indicates more damage.
Time frame: Up to Week 28
Time frame: Up to Week 28
Time frame: Up to Week 28
Time frame: Up to Week 28
Time frame: Baseline, Week 8
Time frame: Baseline, Week 8
VCIEL score is a calculation using the standardized Vh:Cd and standardized IEL. The standardized Vh:Cd is calculated as the difference between the mean Vh:Cd subtracted from each Vh:Cd divided by the Vh:Cd standard deviation. The standardized IEL is calculated as the difference between the mean IEL subtracted from each IEL divided by the IEL standard deviation. VCIEL is the standardized Vh:Cd minus the standardized IEL.
Teva Branded Pharmaceutical Products R&D LLC
Industry
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06908057
Autoimmune Diseases, Celiac Disease
Orlando, Florida, United States
View Trial DetailsNCT06557772
Celiac Disease, Coeliac Disease
Scottsdale, Arizona, United States
View Trial DetailsNCT06717841
Autoimmune Diseases, Celiac Disease
Bologna, Italy
View Trial DetailsNCT05548166
Celiac Disease, Celiac Disease in Children
Hamilton, Ontario, Canada
View Trial Details